Skip to main content
. Author manuscript; available in PMC: 2017 Oct 25.
Published in final edited form as: Clin Breast Cancer. 2012 Apr;12(2):81–86. doi: 10.1016/j.clbc.2012.01.001

Table 5.

Comparison of Present Study With Phase III Studies of Capecitabine With Trastuzumab or Lapatinib

Treatment Regimen Source PFS, mo RR, % OS, mo
Cap Geyer et al (23) 4.4 15 NR
Cap and lapatinib Geyer et al (23) 8.4 22 NR
Cap von Minckwitz et al (21) 5.6 27 20.4
Cap and T von Minckwitz et al (21) 8.4 48 24
Cap, T, and V Present study 11.3 67 27

Abbreviations: Cap, capecitabine; NR, not reported; OS, overall survival; PFS, progression-free survival; RR, response rate; T, trastuzumab; V, vinorelbine.